Testing Whether Early Treatment Can Change the Course of Alzheimer’s Disease
Can anti-amyloid antibody treatment reverse Alzheimer’s disease pathology before memory loss sets in?
Safe Care CommitmentGet the care you need even during COVID-19.Learn more
I am a board certified neurologist who has been working in aging and Alzheimer's Disease (AD) imaging research for 15 years. My laboratory is focused on elucidating the neural underpinnings of memory loss in early Alzheimer's disease (AD) and developing neuroimaging markers of progression in preclinical and prodromal stages of AD. My work includes multiple imaging modalities including functional and structural MRI and PET amyloid imaging. I serve as the Director of the Neuroimaging Program at the Massachusetts Alzheimer's Disease Research Center (ADRC) at Massachusetts General Hospital. I also lead the AD clinical trials program across Brigham and Women's Hospital and Massachusetts General Hospital. I serve on the Steering committee of the Alzheimer's Disease Cooperative Study (ADCS), the Alzheimer's Disease Neuroimaging Initiative (ADNI), and the Dominantly Inherited Alzheimer Network (DIAN), and have the honor of chairing the National Institute on Aging/Alzheimer's Association Workgroup on Preclinical AD.
Clinical Interests:
Treats:
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Phone: 617-726-5571
Fax: 617-726-5760
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and the only hospital to be recognized in all 16 specialties assessed by U.S. News & World Report.
Can anti-amyloid antibody treatment reverse Alzheimer’s disease pathology before memory loss sets in?